Thermo Fisher Scientific (TMO) Accounts Payables (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Accounts Payables for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 9.66% year-over-year to $3.3 billion; the trailing twelve-month figure through Jun 2026 stood at $3.3 billion (up 9.66% YoY), and the FY2025 full-year result was $3.6 billion, up 17.64% from the prior year.
• Accounts Payables fell to $3.3 billion in Q2 2026 per TMO's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Accounts Payables topped out at $3.6 billion in Q4 2025 and bottomed at $2.4 billion in Q3 2023.
• Historically, Accounts Payables has averaged $2.9 billion across 5 years, with a median of $2.8 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables advanced 24.28% in 2022, then retreated 15.05% in 2023.
• Over 5 years, Accounts Payables stood at $3.4 billion in 2022, then declined by 15.05% to $2.9 billion in 2023, then increased by 7.21% to $3.1 billion in 2024, then increased by 17.64% to $3.6 billion in 2025, then decreased by 9.77% to $3.3 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.3 billion, $3.3 billion, and $3.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.